Published Date: 24 Apr 2023
Germany: One mechanism underlying the rise in has been revealed by a research team at the University of Cologne's CECAD Cluster of Excellence in Aging Research.
Read Full News(Refiles to remove extraneous word years from first paragraph)
The Moderna vaccine will likely be available in Europe long before the US.
Saline lavage, alone or combined with intrapleural enzyme therapy, confers no clinically meaningful advantage over intrapleural enzyme therapy alone in patients with pleural infection.
Many doctors facing racism from patients stay silent, doubting they’ll be heard. Experts share strategies for handling bias when institutions fall short.
In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus islatravir shows efficacy and safety similar to standard ART regimens.
Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.
The 2025 update integrates new risk estimation tools and shifts acute coronary syndrome management toward earlier intensive lipid-lowering therapy.
1.
It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.
2.
Bayer is transforming pharmaceutical research into women's health
3.
Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma
4.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
5.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
Decoding Efficacy, Safety, and Future Frontiers in CAR-T Cell Therapy for Hematologic Malignancies Towards CAR-T Therapy 2025
3.
Chondroma: What it is and How it Affects Your Health
4.
Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer
5.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation